Upvote
Downvote
Oncology Territory Manager, Northeast
Share Job
- Suggest Revision
Full-time
- Enabled by our proprietary drug discovery platform, Deciphera has developed a diverse pipeline of wholly-owned drug candidates.
- QINLOCK® (ripretinib) is Deciphera’s switch control inhibitor developed for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United States, and the United Kingdom.
- We wholly own QINLOCK and all of our drug candidates with the exception of a development and commercialization out-license agreement for QINLOCK in Greater China.
- Partnering with cross-functional commercial partners such as market access and medical teams to provide comprehensive solutions for customers.
- Becoming a true subject matter expert on all key topics that impact the success of the business – GIST and TGCT disease state knowledge, clinical acumen, product expertise, competitive intelligence, market dynamics, customer needs across segments, local market access, etc.
Active Job
Updated 5 days agoSimilar Job
Relevance
Active